Breakthrough Medicine: Will Finding a Cure Be Just the Start of Saving Lives?

Melanoma Research Alliance (MRA) Overview

• Founded in 2007 by Deborah and Leon Black under the Milken Institute as a unique nonprofit.
• Has funded $68 million in research globally focused on identifying treatments for late-stage melanoma.
• Melanoma incidence is rising, claiming one patient every hour in the U.S. and tens of thousands globally.
• Without treatment, most late-stage patients have a prognosis of less than one year.
• Initiated a "skin check pledge" campaign committing $250,000 to research (in $100 increments per pledge).

Current Therapeutic Landscape & Breakthroughs

• Eight new melanoma treatments have been approved since 2011, including personalized medicine and immunotherapy.
• Immunotherapy approaches work by removing immune system "brakes" to allow the body to recognize cancer as foreign.
• Targeted therapies targeting BRAF and NRAS mutations provide 70-80% response rates but high rates of relapse.
• Immunotherapies show lower initial response rates but more durable results.
• Median survival for melanoma patients has accelerated from 6-8 months to nearing two years within the last two to three years.
• Advances are being applied beyond melanoma to lung cancer, breast cancer, lymphoma, cystic fibrosis, HIV/AIDS, and diabetes.

Challenges in Access and Delivery

• Cost Barriers: High costs of developing breakthrough drugs threaten both innovators and payers; infusion drugs require practices to stock inventory, creating financial risk for small groups.
• Reimbursement Lag: New drugs take time to get insurance codes and Medicare approval, delaying patient access.
• Small Practice Viability: Independent clinicians lack the funding and bandwidth to absorb drug costs or hire business administrators, leading to practice consolidation.
• Education Gaps: Physicians often lack training in genomics, informatics, and new treatment pathways.
• Dissemination: There is a struggle to communicate off-label or emerging data without violating drug labeling constraints.

The Role of Precision and Individualized Medicine

• Mayo Clinic established the Center for Individualized Medicine to address genomic challenges and "medical mysteries."
• Genomic sequencing can solve "diagnostic odysseys," providing answers for approximately 30% of patients with undiagnosed complex conditions.
• Shifts focus from organ-based classification to molecular-based treatment (e.g., treating a lung cancer with melanoma-like mutations).
• Example Case: A 51-year-old with cholangiocarcinoma, initially bedridden, saw liver tumors shrink by two-thirds and regained quality of life after targeted immunotherapy based on genomic findings.
• Future application includes sequencing healthy individuals to predict and mitigate risks for heart disease, diabetes, and Alzheimer's, balanced against ethical concerns of "forewarning."

Strategic Shifts in Healthcare Delivery

• Data Utilization: Insurers and providers are deploying real-time data pipelines (e.g., Blue Cross's Navinet) to predict chronic conditions like diabetes before onset.
• Algorithmic Care: Organizations like Mayo are scaling knowledge by sharing clinical decision algorithms with over 32 external healthcare organizations.
• Chronic Disease Model: The goal is to transform cancer and other diseases into manageable chronic conditions, similar to the trajectory of HIV and CML.
• Medical Education Reform: Mayo is revamping medical curricula to include informatics, engineering, and business skills to prepare physicians for data-driven care.

Panel Consensus on Future Actions and Solutions

• Collaboration: Universal agreement that cross-sector partnership (pharma, providers, payers, nonprofits) is the primary driver for innovation and patient access.
• Nonprofit Intermediation: Nonprofits are critical in mediating pre-clinical and clinical collaborations and educating patients/physicians.
• Regulatory Streamlining: The FDA is encouraged to further streamline development processes to reduce the typical 10-12 year timeline.
• Mentorship: Establishing mentorship networks is vital to replicate institutional knowledge and foster future collaboration.
• Aligned Incentives: True collaboration requires incentive-based programs where insurers, providers, and manufacturers share in cost savings and outcome improvements.
• Funding Concerns: NIH funding has remained flat (decreasing in real dollars), while clinical revenues are declining, increasing reliance on public-private partnerships.

Forward-Looking Statements

• The healthcare system aims to scale personalized care from serving 1.3 million patients to 200 million by 2020.
• Diabetes rates are projected to rise from 25 million to a 25% increase in prevalence by 2050 without intervention.
• The panel anticipates a future where tumor sequencing and immediate genomic analysis become standard of care, though this remains several years away.
• The industry aims to transform the patient experience from "getting affairs in order" (as was common with HIV in the 80s) to living near-normal life expectancies.